About
thirty affected individuals having more than 55 years old are diagnosed with
Acute Lymphoblastic Leukemia (ALL) that is included in Phase II trial. All the
affected individuals received various doses of erythrocyte encapsulated
Asparaginase that is in conjunction with the chemotherapy. It is mostly recommended
by the European Working group for Adult Lymphoblastic Leukemia (EWALL).
Most
of the medical experts said that the Asparaginase is the powerful medication to
cure ALL, but at present, this dose is not given to the treatment for those old
affected individuals who are particularly weak for toxicity reasons. Erythrocyte
encapsulated Asparaginase is the first induction treatment that has shown
positive safety profile even in the old aged affected individuals.
At
the normal dosage of the medicine, 91% of the affected individuals at the end
of the treatment reached to lowest level and an average overall survival was
15.6 months. The enrolment of the affected individuals was ended up in
expectations.
No comments:
Post a Comment